Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer – a population-based case-control study

British Journal of Cancer

Volumn 68, Issue 1, 1993, Pages 97-102

  Andersson, S O ^a,b   Adami, H O ^b   BergstrOm R ^c   Wide, L ^b  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; HYPOPHYSIS HORMONE; LUTEINIZING HORMONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; ANDROSTENEDIONE; CASE-CONTROL STUDIES; ESTRADIOL; FOLLICLE STIMULATING HORMONE; HUMAN; LUTEINIZING HORMONE; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REGISTRIES; SEX HORMONE-BINDING GLOBULIN; SUPPORT, NON-U.S. GOV'T; SWEDEN; TESTOSTERONE;

EID: 0027195511     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.293     Document Type: Article

References (38)

1. AHLUWALIA, B., JACKSON, M.A., JONES, G.W., WILLIAMS, A.O., RAO, M.S. & RAJGURU, S. (1981). Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer, 48, 2267-2273.
2. BARRACK, E.R., BUJNOVSKY, P. & WALSH, P.C. (1983). Subcellular distribution of androgen receptors in human normal, benign hyperplasia and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res,. 43, 1107-1116.
3. BARRETTCONNOR, E., GARLAND, C., MCPHILLIPS, J.B., KHAW, K.T. & WINGARD, D.L. (1990). A prospective, population-based study of androstenedione, estrogens and prostatic cancer. Cancer Res., 50, 169-173.
4. BARTSCH, W., STEINS, P. & BECKER, H. (1977a). Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation. Eur. Urol., 3, 47-52
5. BARTSCH, W., HORST, H.-J., BECKER, H. & NEHSE, G. (1977). Sex hormone binding globulin capacity, testosterone, 5-alfa-di- hydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol,. 85, 650-664.
6. COFFEY, D.S. & ISAACS, J.T. (1981). Control of prostate growth. Urology, Suppl. 3, 17-24.
7. DAI, W.S., KULLER, L.H., LAPORTE, R.E., GUTAI, P., FALVOGERARD, L. & GAGGIULA, A. (1981). The epidemiology of plasma testosterone levels in middle-aged men. Am. J. Epidemiol., 114, 804-816.
8. DE VITA, V.T., HELLMAN, S. & ROSENBERG, S.A. (1982). Cancer: Principles and practise of Oncology. Lippincott: Philadelphia.
9. DRAFTA, D., PROCA, E., ZAMFIR, V., SCHINDLER, A.E., NEACSU, E. & STROE, E. (1982). Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J. Steroid Biochem., 17, 689-693.
10. GHANADIAN, R., PUAH, C M. & O’DONOGHUE, E.P.N. (1979). Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br. J. Cancer, 39, 696-699.
11. GREENWALD, P. Prostate. In: Schottenfeld, D. & Fraumeni, J.F., Jr. (eds) (1982). Cancer Epidemiology and Prevention, pp. 9138-9146. Saunders: Philadelphia.
12. HABIB, F.K. (1980). Evaluation of androgen metabolism studies in human prostate cancer: correlation with zinc level. Prevent. Med., 9, 650-656.
13. HABIB, F.K., ODOMA, S., BUSUTTIL, A. & CHISHOLM, G.D. (1986). Androgen receptors in cancer of the prostate - correlation with the stage and grade of the tumor. Cancer, 57, 2351-2356.
14. HAMMOND, G., KONTTURI, M., VIHKO, P. & VIHKO, R. (1978). Serum steroids in normal males and patients with prostatic diseases. Clin. Endocrinol., 9, 113-121.
15. HARPER, M.E., PEELING, W.B., COWLEY, T., BROWNSEY, B.G., PHILLIPS, M.E.A., GROOM, G., FAHMY, D R. & GRIFFITHS, K. (1976). Plasma steroid and protein hormone concentrations in patients with prostate cancer before and during oestrogen therapy. Acta Endocrinol. (Copenh)., 81, 409-426.
16. HILL, P., WYNDER, E.L., GARBACZEWSKI, L. & WALKER, A.R.P. (1982). Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res., 42, 3864-3869.
17. HØISAETER, P.A., HAUKAAS, S., BAKKE, A., HOIEM, L., SEGADAL, E. & THORSEN, T. (1982). Blood hormone levels related to stages and grades of prostatic cancer. Prostate, 3, 375-381.
18. HSING, A. & COMSTOCK, G. (1989). Serum hormone and risk of subsequent prostate cancer. Am. J. Epidemiol., 130, 829.
19. HUGGINS, C. & HODGES, C.V. (1941). Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 43, 209-223.
20. HULKA, B.S., HAMMOND, J.E., DIFERNANDO, G., MICKEY, D.D., FRIED, F.A., CHECKOWAY, H., STUMPF, W.E., BECKMAN, W.C. & CLARK, T.D. (1987). Serum hormone levels among patients with prostatic carcinoma or benign prostatic hypertrophy and clinic controls. Prostate, 11, 171-182.
21. INTERNATIONAL HISTOLOGICAL CLASSIFICATION OF TUMORS. No 22 (1980). Histological Typing of Prostate Tumors. WHO: Geneva.
22. ISHIKAWA, S., SOLOWAY, M.S., VAN DER ZWAAG, R. & TODD, B. (1989). Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J. Urol., 14, 1139.
23. JACKSON, M.A., KOVI, J., HESHMAT, M.Y., OGUNMUYIWA, T.A., JONES, G.W., WILLIAMS, A.O., CHRISTIAN, E C., NKPOSONG, E.O., RAO, M.S., JACKSON, A.G. & AHLUWALIA, B. (1980). Characterization of prostatic carcinoma among blacks: a comparison between a low-incidence area, Ibadan, Nigeria, and a high- incidence area, Washington DC. Prostate, 1, 185-205.
24. JACOBI, G.H., RATHGEN, G.H. & ALTWEIN, J.E. (1980). Serum prolactin and tumors of the prostate: unchanged, basal levels and lack of correlation to serum testosterone. J. Endocrinol., 3, 15-18.
25. LEVELL, M.J., ROWE, E., GLASHAN, R.W., PIDCOCK, N.B. & SIDDALL, J.K. (1985). Free testosterone in carcinoma of the prostate. Prostate, 7, 363-367.
26. MEIKLE, A.W. & STANISH, W. (1982). Familial prostatic cancer risk and low testosterone. J. Clin. Endocrinol. Metabol., 54, 1104-1108.
27. MEIKLE, A.W., SMITH, J.A. & STRINGHAM, J.D. (1989). Estradiol and testosterone metabolism and production in men with prostatic cancer. J. Steroid Biochem., 33, 19-24.
28. NOBLE, R.L. (1977). The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37, 1929-1933.
29. NOMURA, A., HEILBRUN, L.K., STEMMERMANN, G.N. & JUDD, H.J. (1988). Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res., 48, 3515-3517.
30. RANIKKO, F.S. & ADLERCREUTZ, H. (1983). Plasma estradiol, free testosterone, sex hormone binding globulin capacity and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate, 4, 223-229.
31. ROSS, R., BERNSTEIN, L., JUDD, H., HANISCH, R., PIKE, M. & HENDERSON, B. (1986). Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst., 76, 45-48.
32. ROSS, R., BERNSTEIN, L., LOBO, R., SHIMIZU, H., STANCZYK, F., PIKE, M. & HENDERSON, B. (1992). 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339, 887-889.
33. SAROFF, J., KIRDANI, R.Y., MING CHU, T., WAJSMAN, Z. & MURPHY, G. (1980). Measurements of prolactin and androgens in patients with prostatic diseases. Oncology, 37, 46-52.
34. SODERGARD, R., BACKSTROM, T., SHAN BHAG, V. & CARSTENSEN, H. (1982). Calculation of free and bound fractions of testosterone and estradiol-17p to human plasma proteins of body temperature. J. Steroid Biochem., 16, 801-810.
35. THE CANCER REGISTRY (1991). Cancer Incidence in Sweden 1988. National Board of Health and Welfare: Stockholm.
36. UICC. UNION INTERNATIONALE CONTRE LE CANCER (1978). TNM Classification of Malignant Tumours. Third edition. International Union against Cancer: Geneva.
37. YOUNG, H. & KENT, J. (1968). Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J. Urol., 99, 788-792.
38. ZUMOFF, B., LEVIN, J., STRAIN, G.W., ROSENFELD, R.S., O’CONNOR, J., FREED, S.Z., KREAM, J., WHITMORE, W., FUKUSHIMA, D. & HELLMAN, L. (1982). Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a ‘two-disease’ theory. Prostate, 3, 579-588.